ProMIS Neurosciences Inc
TSX:PMN

Watchlist Manager
ProMIS Neurosciences Inc Logo
ProMIS Neurosciences Inc
TSX:PMN
Watchlist
Price: 6 CAD -3.85% Market Closed
Market Cap: 51.5m CAD

ProMIS Neurosciences Inc
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ProMIS Neurosciences Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
ProMIS Neurosciences Inc
TSX:PMN
Change in Working Capital
$7.1m
CAGR 3-Years
94%
CAGR 5-Years
N/A
CAGR 10-Years
53%
Theratechnologies Inc
TSX:TH
Change in Working Capital
-$5.7m
CAGR 3-Years
N/A
CAGR 5-Years
-64%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Change in Working Capital
-$4.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Change in Working Capital
$7.2m
CAGR 3-Years
N/A
CAGR 5-Years
76%
CAGR 10-Years
12%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Change in Working Capital
-$2.4m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Spectral Medical Inc
TSX:EDT
Change in Working Capital
CA$160k
CAGR 3-Years
13%
CAGR 5-Years
-53%
CAGR 10-Years
-7%
No Stocks Found

ProMIS Neurosciences Inc
Glance View

Market Cap
51.5m CAD
Industry
Biotechnology

ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).

PMN Intrinsic Value
Not Available

See Also

What is ProMIS Neurosciences Inc's Change in Working Capital?
Change in Working Capital
7.1m USD

Based on the financial report for Mar 31, 2023, ProMIS Neurosciences Inc's Change in Working Capital amounts to 7.1m USD.

What is ProMIS Neurosciences Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
53%

The average annual Change in Working Capital growth rates for ProMIS Neurosciences Inc have been 94% over the past three years , and 53% over the past ten years .

Back to Top